KEYTRUDA® (Pembrolizumab)

RR FDA Approvals
Head & Neck: Hypopharynx Head & Neck: Larynx (Glottis) Head & Neck: Larynx (Subglottis) Head & Neck: Larynx (Supraglottis) Head & Neck: Lip and Oral Cavity Head & Neck: Oropharynx

The FDA on June 10, 2019 approved KEYTRUDA® for the first-line treatment of patients with metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC). KEYTRUDA® is a product of Merck.

Related Posts: